BiologicalDrug

BTH1677 clinical trials

Also written BTH-1677 and Odetiglucan.

studies test it: 15
open now: 2
in phase 3: 1
first study started: 2007

Keep track of what changes. Save the BTH1677 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

15 studies that test it; most in 2017 (3)

Studies that test BTH1677, by start year
Year	Studies
2007	1
2009	2
2011	2
2014	1
2017	3
2018	1
2021	2
2022	1
2025	2

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 2: 12
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung: 3
Colorectal Neoplasms: 2
Carcinoma: 1
Triple Negative Breast Neoplasms: 1
Breast Neoplasms: 1
Leukemia, Lymphocytic, Chronic, B-Cell: 1
Adenocarcinoma: 1
Squamous Cell Carcinoma of Head and Neck: 1
Pancreatic Neoplasms: 1
Melanoma: 1

Who runs them

Industry 10 · Other 5

HiberCell, Inc. (9) · Lawrence Feldman, MD (1) · Mayo Clinic (1) · Abramson Cancer Center at Penn Medicine (1) · University of Pennsylvania (1) · Hoffmann-La Roche (1) · University of Illinois at Chicago (1)

Often tested with

Tested in the same studies.

Pembrolizumab (5) · Irinotecan (1) · Alemtuzumab (1) · Rituximab (1) · Mitazalimab (1) · CDX-1140 (1) · Regorafenib (1) · Atezolizumab (1)

Studies

Open first, then newest update. How each study uses BTH1677 is read from its arms, and is right about nine times in ten.

Testing it · 15

Given in every arm · 1 — BTH1677 is usual care beside what is tested

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaCompletedPhase 2Dana-Farber Cancer InstituteNCT02086175Written as Imprime PGG

BTH1677 clinical trials

How studies write it

Name

Development codes

Other names

Combined with it in one product